| 16.25 -0.21 (-1.28%) | 10-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.02 | 1-year : | 26.88 |
| Resists | First : | 19.7 | Second : | 23.02 |
| Pivot price | 17.2 |
|||
| Supports | First : | 14.82  |
Second : | 11.81 |
| MAs | MA(5) : | 16.53 |
MA(20) : | 17.41 |
| MA(100) : | 12.42 |
MA(250) : | 13.88 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 34.9 |
D(3) : | 39.5 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 28.09 | Low : | 7.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCAX ] has closed above bottom band by 23.8%. Bollinger Bands are 2.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.95 - 17.03 | 17.03 - 17.1 |
| Low: | 15.7 - 15.81 | 15.81 - 15.9 |
| Close: | 16.1 - 16.26 | 16.26 - 16.4 |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Thu, 16 Oct 2025
Bicara Therapeutics CEO Mazumdar sells $466k in shares - Investing.com India
Wed, 08 Oct 2025
Bicara Therapeutics CFO Hyep Ivan sells $553,198 in shares - Investing.com
Wed, 08 Oct 2025
Bicara therapeutics president Cohlhepp sells $911k in shares - Investing.com
Mon, 16 Sep 2024
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
Tue, 27 Aug 2024
Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug (Pending:BCAX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 94 (%) |
| Shares Short | 5,680 (K) |
| Shares Short P.Month | 5,670 (K) |
| EPS | -4.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -32.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -3.49 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|